Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.

被引：0
|
作者：
Souglakos, J [1 ]
Kouroussis, C [1 ]
Ziras, N [1 ]
Malamos, N [1 ]
Potamianou, A [1 ]
Mavroudis, D [1 ]
Kakolyris, S [1 ]
Androulakis, N [1 ]
Vardakis, N [1 ]
Georgoulias, V [1 ]
机构：
[1] Greek Cooperat Grp GI Tumors, Heraklion, Greece
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215P
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [1] Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC):: A phase I/II study.
    Miyata, Y
    Shirao, K
    Ohtsu, A
    Boku, N
    Tanigawara, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 295S - 295S
  • [2] Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) - A phase II study.
    Tsavdaridis, D
    Athanasiadis, A
    Pissanidis, N
    Saleh, M
    Moshidis, A
    Chatzichristou, A
    Makrantonakis, N
    Kamentsidis, P
    Natsiopoulos, I
    Christakis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 297S - 297S
  • [3] Second and third-line chemotherapy (CT) with oxaliplatin L-OHP), 5-fluorouracil (FU) and leucovorin (LV) in patients (pts) with advanced colorectal cancer (ACC): a new schedule.
    D'Andrea, M
    Bari, M
    Sartori, D
    Silvestri, B
    Azzarello, G
    Rosetti, F
    Zardo, S
    Porcellini, A
    Vinante, O
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [4] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [5] Oxaliplatin (L-OHP) does not influence the pharmacokinetics of 5-fluorouracil (5-FU)
    Joel, SP
    Richards, F
    Halstead, F
    Seymour, M
    BRITISH JOURNAL OF CANCER, 2000, 83 : 68 - 68
  • [6] Synergistic interaction between oxaliplatin (L-OHP) and 5-Fluorouracil (5-FU)
    Ward, S
    Papamichael, D
    Locke, K
    Darke, C
    Joel, S
    ANNALS OF ONCOLOGY, 1998, 9 : 39 - 39
  • [7] Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5FU
    Beretta, GD
    Cascinu, S
    Zaniboni, A
    Ratti, R
    Giordani, P
    Catalano, V
    Martignoni, G
    Barni, S
    Frontini, L
    Labianca, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S80 - S80
  • [8] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [9] Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP).
    Papamichael, D
    Joel, SP
    Seymour, M
    Richards, F
    Bowerbank, M
    Slevin, ML
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12
  • [10] Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer(ACC)
    Punt, CJA
    Keizer, HJ
    Douma, J
    Schüller, J
    Skovsgaard, T
    ten Napel, CHH
    Lochs, H
    Muller, EW
    Russell, L
    Wagener, DJT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
12345